High-Purity Research Peptides with Free Shipping Within the U.S.
CJC - 1295 (no DAC) / Ipamorelin
CJC-1295 (no DAC), Ipamorelin (Blend)
$75.00
Quantity
Description
CJC‑1295 (no DAC) combined with Ipamorelin represents a balanced peptide strategy for growth hormone support and healthy aging. CJC‑1295 (no DAC) acts as a GHRH analog, stimulating natural GH release without the prolonged activity of DAC modification, while Ipamorelin provides selective secretagogue action with minimal off‑target effects. Together, they encourage pulsatile GH secretion, boost IGF‑1 production, and promote cellular repair, recovery, and metabolic efficiency. This blend is being investigated for benefits in lean muscle preservation, fat metabolism, tissue regeneration, and resilience against age‑related decline, positioning it as a candidate for enhancing vitality and long‑term performance.
Additional Information
Weight: 0.08 lbs
Dimensions: 0.87 × 1.18 × 0.87 in
Size: 500mg, 1000mg
This product is intended solely for research purposes. It is not authorized for use in humans or animals and should only be handled by trained personnel in appropriate laboratory settings.
Highlights
Structural Properties
Stability: Sensitive to light and moisture
Solubility: Soluble in sterile water and acetic acid
Storage Conditions: Store at 36‑46 °F (2‑8 °C)
Form: Lyophilized white powder
Peptide Composition
CJC‑1295 (no DAC): 5 mg — Modified GRF 1‑29 analog
Ipamorelin: 5 mg — Selective pentapeptide secretagogue
Total Content: 10 mg lyophilized peptide
Blend Ratio: 1:1 balanced formulation
Biological Mechanism
The pairing delivers a strong synergistic effect by targeting complementary pathways in growth hormone secretion.
CJC‑1295 (no DAC) – Key Actions
GHRH Analog Activity
Engineered variant of GHRH (1‑29) designed for improved stability
Prolonged Half‑Life
Extends activity to ~30 minutes compared to ~7 minutes for native GHRH
Enhanced Pulse Frequency
Supports more frequent growth hormone release cycles
Resistance to Breakdown
Four amino acid substitutions protect against enzymatic degradation
Ipamorelin – Key Actions
Ghrelin Receptor Targeting
Precisely engages GHS‑R1a receptors
Amplified Pulse Strength
Boosts the amplitude of each GH release
Selective Profile
Does not influence cortisol, prolactin, or ACTH
Rapid Effect
Fast‑acting with an approximate 2‑hour half‑life
Combined Synergistic Effects
When used together, these peptides amplify growth hormone output by engaging complementary mechanisms of release:
3–5x GH Elevation: Achieves growth hormone levels markedly greater than with either peptide individually
Physiological Pulsatility: Preserves the body’s natural rhythm of GH release
Sustained Activity: Delivers longer‑lasting effects while initiating action rapidly
Targeted Specificity: Stimulates GH exclusively, without altering cortisol, prolactin, or other hormones
Research Highlights
This formulation holds distinct value for advancing comprehensive studies on growth hormone regulation and function:
Recovery and Regeneration
Evidence points to accelerated repair and recovery:
• Faster post‑exercise recovery times
• Improved connective tissue healing
• Strengthened bone mineral density
• Quicker wound healing
• Reduced downtime between training sessions
Sleep and Well‑Being
Studies on quality of life parameters show:
• Better deep sleep quality
• Enhanced REM sleep cycles
• Improved mood and cognitive clarity
• Higher energy levels
• Greater resilience to stress
Age‑Related Research
Research into longevity markers demonstrates:
• Improved skin elasticity and thickness
• Increased collagen synthesis
• Enhanced cellular regeneration
• Reduced age‑related muscle decline
• Better mitochondrial performance
Cardiovascular Health
Cardiac and vascular benefits include:
• Improved cardiac output
• Enhanced endothelial function
• Healthier lipid profiles
• Lower inflammatory markers
• Greater vascular flexibility
Metabolic Function Studies
Research highlights notable metabolic enhancements:
• Greater fat breakdown and lipolysis
• Improved markers of insulin responsiveness
• More efficient glucose utilization
• Elevated metabolic rate
• Optimized nutrient distribution
Body Composition Research
Findings indicate positive changes in tissue quality:
• Increased development of lean muscle mass
• Lower body fat percentage
• Enhanced muscle protein synthesis
• Improved muscle‑to‑fat ratio
• Overall body recomposition benefits
Research Advantages
Reasons this blend is favored in growth hormone studies:
Research Versatility
Balanced 1:1 ratio simplifies dosing and study design
Targeted Specificity
Stimulates GH exclusively, with no impact on cortisol or prolactin
Complementary Dynamics
Rapid onset from Ipamorelin paired with extended activity from CJC‑1295
Consistent Response
Maintains potency without desensitization during ongoing research applications
Enhanced Effectiveness
Delivers a 3–5× increase in GH release compared to individual peptides
Physiological Secretion
Preserves the body’s natural pulsatile growth hormone rhythm
It should be emphasized that these observations are generally minor and short‑lived in research settings, with no documented cases of severe adverse reactions or dependency concerns typically linked to conventional anxiolytic agents.
Important Information: This material is restricted to experimental laboratory work and must not be used in humans or animals.
References
Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 2020. — Ishida J, et al.
Beyond the androgen receptor: the role of growth hormone secretagogues in body composition. Transl Androl Urol, 2020. — Deepankar K, et al.
Immuno-PCR detection of CJC‑1295 and GH-releasing hormone analogs. Drug Test Anal, 2019. — Walpurgis K, et al.
Activation of the GH/IGF‑1 axis by CJC‑1295. Growth Horm IGF Res, 2009. — Sackmann‑Sala L, et al.
Synergistic GH release via GHRH and GHRP co‑administration. Pituitary, 2009. — Veldhuis JD, et al.
Persistence of pulsatile GH secretion under continuous stimulation. J Clin Endocrinol Metab, 2006. — Ionescu M, Frohman LA.
Prolonged GH and IGF‑I stimulation with CJC‑1295. J Clin Endocrinol Metab, 2006. — Teichman SL, et al.
Once‑daily dosing of CJC‑1295: endocrine outcomes. J Clin Endocrinol Metab, 2005. — Alba M, et al.
Comparative effects of ipamorelin and GHRP‑6. Peptides, 2002. — Beck DE, et al.
Ipamorelin’s influence on the GH/IGF‑1 axis. Growth Horm IGF Res, 2001. — Jimenez‑Reina L, et al.
Pharmacokinetics and dynamics of ipamorelin. J Clin Pharmacol, 1999. — Gobburu JV, et al.
Ipamorelin: the first selective GH secretagogue. Eur J Endocrinol, 1998. — Raun K, et al.
About Us
Zenergen Research Products is committed to supplying high-purity peptides intended for research use, with an emphasis on quality control and dependable delivery.
Contact Us
Copyright© 2026 Zenergen Research - All Rights Reserved.